An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Provided herein are novel triazolopyridine derivatives as DGAT2 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.
The author declares no competing financial interest.
References
Esler W. P.; Cohen D. E. Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. J. Hepatol. 2024, 80, 362–377. 10.1016/j.jhep.2023.10.042.
-
DOI
-
PMC
-
PubMed
Deng B.; Kong W.; Shen X.; Han C.; Zhao Z.; Chen S.; Zhou C.; Bae-Jump V. The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications. J. Transl. Med. 2024, 22, 290. 10.1186/s12967-024-05084-z.
-
DOI
-
PMC
-
PubMed
Huttasch M.; Roden M.; Kahl S. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?. Metabolism 2024, 157, 155937. 10.1016/j.metabol.2024.155937.
-
DOI
-
PubMed
Wolk M.; Fedorova M. The lipid droplet lipidome. FEBS Lett. 2024, 598, 1215–1225. 10.1002/1873-3468.14874.
-
DOI
-
PubMed
Sabnis R. W. Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases. ACS Med. Chem. Lett. 2024, 15, 1180–1181. 10.1021/acsmedchemlett.4c00286.
-
DOI
-
PMC
-
PubMed